Forte Biosciences, Inc. (FBRX) Net Income (Loss) Attributable to Parent USD 2016 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Forte Biosciences, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2016 to 2024.
  • Forte Biosciences, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$7.42 M, a 9.88% decline year-over-year.
  • Forte Biosciences, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$32.1 M, a 77.9% decline year-over-year.
  • Forte Biosciences, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$31.5 M, a 127% decline from 2022.
  • Forte Biosciences, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$13.9 M, a 36.1% increase from 2021.
  • Forte Biosciences, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$21.7 M, a 53.3% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$32.1 M -$7.42 M -$667 K -9.88% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$31.5 M -$5.87 M -$995 K -20.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-18
Q3 2023 -$30.5 M -$9.96 M -$6.56 M -193% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$23.9 M -$8.9 M -$5.86 M -193% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-13
Q1 2023 -$18.1 M -$6.75 M -$4.19 M -163% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$13.9 M -$4.88 M -$1.54 M -46% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-18
Q3 2022 -$12.3 M -$3.4 M +$4.35 M +56.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$16.7 M -$3.04 M +$2.78 M +47.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$19.5 M -$2.57 M +$2.24 M +46.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$21.7 M -$3.34 M +$1.24 M +27% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$22.9 M -$7.75 M -$2.65 M -52% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$20.3 M -$5.81 M +$28.9 M +83.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$49.2 M -$4.8 M -$2.75 M -134% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$46.5 M -$4.58 M +$6.01 M +56.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$52.5 M -$5.1 M -$4.41 M -639% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$48.1 M -$34.8 M -$34.1 M -5418% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-08
Q1 2020 -$14 M -$2.05 M -$865 K -73% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-08
Q4 2019 -$13.1 M -$10.6 M +$9.02 M +46% Oct 1, 2019 Dec 31, 2019 10-K 2020-02-27
Q3 2019 -$22.1 M -$690 K -$307 K -80.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$21.8 M -$630 K +$15.5 M +96.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-09
Q1 2019 -$37.3 M -$1.19 M +$11.7 M +90.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-09
Q4 2018 -$49 M -$19.6 M -$8.77 M -80.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$40.2 M -$383 K +$9.57 M +96.2% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$49.8 M -$16.1 M -$7.02 M -77.5% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$42.7 M -$12.9 M -$3.81 M -42% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$38.9 M -$10.8 M -$2.41 M -28.6% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 -$36.5 M -$9.95 M -$953 K -10.6% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-27
Q2 2017 -$35.6 M -$9.07 M -$1.02 M -12.7% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-27
Q1 2017 -$34.5 M -$9.07 M -$1.07 M -13.3% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-27
Q4 2016 -$33.5 M -$8.43 M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-09
Q3 2016 -$9 M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-09
Q2 2016 -$8.04 M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-09
Q1 2016 -$8.01 M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.